Porton Fine Chemicals vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Porton Fine Chemicals Ltd (300363.CS)

Q3 202614 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

August 202614 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

Latest14 Jul – 24 Aug 2026

▲3▼1

Porton swings to loss on Slovenia writedown, but core profit and CGT license advance

Slovenia project termination triggers 330 million yuan impairment and first-half loss Porton expects a first-half 2026 net loss of 210-250 million yuan, versus a profit last year, after scrapping its Slovenia R&D and production base and taking a roughly 330 million yuan writedown. The final interim report confirmed a 224 million yuan loss. This one-time hit is the main reason the stock looks weak on headline numbers.
The impairment is the single biggest swing factor behind the reported loss and the market's negative reaction.
Core profit surges 196-343% excluding impairment on higher revenue and margins Strip out the Slovenia writedown and Porton's underlying profit was 80-120 million yuan, up 196-343% from a year earlier. Revenue rose 8-12% to 1.75-1.82 billion yuan, and gross margin improved about 4 percentage points on higher-margin product deliveries. This shows the operating business is actually getting healthier.
It separates the one-time loss from the real operating performance, which is what long-term investors care about.
Suzhou subsidiary wins first drug manufacturing license for cell and gene therapy Porton's majority-owned Suzhou unit obtained a drug manufacturing license, allowing it to commercially make cell and gene therapy products for clients. This opens a new, higher-value contract manufacturing business and supports future revenue growth beyond its traditional small-molecule work.
It is a concrete regulatory milestone that expands Porton's addressable market into a fast-growing area.
CRO sector rally lifts peers and Porton shares WuXi AppTec's blowout first-half results and raised guidance sent CRO stocks soaring, with the sector index up nearly 8% and Porton hitting its daily limit. Strong demand for outsourced drug development is lifting the whole group, though global GLP-1 capacity expansion is raising competition.
Sector momentum is a major short-term price driver for Porton, even if it is not company-specific.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

August 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

Latest31 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.